FDA approves Revlimid for myeloma maintenance after stem cell transplant – Healio
Oncology Nursing News |
FDA approves Revlimid for myeloma maintenance after stem cell transplant
Healio Lenalidomide (Revlimid, Celgene) is the only FDA–approved treatment for maintenance after autologous HSCT. “Autologous stem cell transplant after induction therapy is part of the continuum of care for transplant-eligible multiple myeloma patients … FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma … Maintenance Revlimid Gains FDA Approval for Multiple Myeloma FDA Approves Maintenance Lenalidomide for Myeloma |
